- Argentina
- Finland
- Japan
- Senegal
- France
- Korea
- Slovakia
- Australia
- Germany
- Malaysia/Singapore
- South Africa
- Austria
- Greece
- Mexico
- Spain
- Belgium
- Hong Kong
- Netherlands
- Sweden
- Brazil
- Hungary
- New Zealand
- Switzerland
- Canada
- India
- Norway
- Taiwan
- China
- Indonesia
- Pakistan
- Thailand
- Colombia
- Ireland
- Philippines
- Turkey
- Czech Republic
- Israel
- Poland
- United Kingdom
- Denmark
- Italy
- Portugal
- Venezuela
Welcome to Pfizer’s News & Media Center—designed to give you immediate access to timely and relevant information about our company. In this section you will find information and resources for journalists including current and archived Pfizer press releases, a full company press kit, and a comprehensive collection of images and videos in our multimedia library.
Pfizer to Continue Evaluation of Inotuzumab Ozogamicin in Other Hematologic Malignancies
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for intensive high-dose chemotherapy.
Pfizer Inc.
Media:
Victoria Davis, 484-865-5194
or
Investors:
Suzanne Harnett, 212-733-8009
Additional Analyses Further Evaluate Safety and Efficacy of Tofacitinib in Rheumatoid Arthritis
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that 11 abstracts for tofacitinib will be presented at the European League Against Rheumatism (EULAR) 2013 Annual Meeting being held June 12-15 in Madrid, Spain. The brand name for tofacitinib is XELJANZ® (ZEL JANS).
Highlights include:
Comparison of monotherapy vs. combination therapy with tofacitinib
Pfizer Inc.
Media Contact:
Victoria Davis
M: 347-558-3455
E: Victoria.Davis@pfizer.com
or
Investor Contact:
Suzanne Harnett
O: 212-733-8009
E: Suzanne.Harnett@pfizer.com
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Morgan Stanley 2013 R&D Seminar: Reigniting Pharma on Friday, May 10, 2013 at 11:00 a.m. Eastern Daylight Time.
Pfizer Inc.
Media:
Joan Campion, 212-733-2798
or
Investors:
Suzanne Harnett, 212-733-8009
- Subgroup analysis demonstrates that the treatment effects of Eliquis® (apixaban) vs. warfarin, across a broad range of warfarin control, are consistent with primary results of ARISTOTLE
- ARISTOTLE studied Eliquis vs. warfarin for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association.
NEW YORK--(BUSINESS WIRE)--To meet the needs of consumers who are increasingly going online to purchase prescription medications, Pfizer today launched Viagra® home delivery, a new prescription-fulfillment website for Viagra® (sildenafil citrate) tablets, Pfizers most counterfeited medicine. The site, which is powered by CVS/pharmacy and accessible through Viagra.com, offers men with erectile dysfunction (ED) an opportunity to purchase Viagra online (with a valid prescription) from a trusted source.
Pfizer
Media Contact:
Jennifer Kokell
(212) 733-2596
(917) 741-4254
Jennifer.Kokell@Pfizer.com
or
Investor Relations:
Suzanne Harnett
(212) 733-8009
- First-Quarter 2013 Revenues of $13.5 Billion, including All Zoetis(1) Revenues
- First-Quarter 2013 Adjusted Diluted EPS(2) of $0.54, Reported Diluted EPS(3) of $0.38
- Repurchased $6.3 Billion of Common Stock to Date in 2013
- Updates 2013 Adjusted Diluted EPS(2) Guidance to Reflect the Impact of Recent Changes in Foreign Exchange Rates and the Zoetis(1) Initial Public Offering
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2013 and updated certain components of its 2013 financial guidance to reflect the impact of recent changes in foreign exchange rates and the initial public offering (IPO) of a 19.8% ownership interest in Zoetis(1) completed on February 6, 2013, among other factors. Pfizer continues to consolidate Zoetis(1), as Pfizer retains an 80.2% ownership interest.
Pfizer Inc.
Media:
Joan Campion, 212-733-2798
Investors:
Suzanne Harnett, 212-733-8009
Teleconference: Prevenar 13
Pfizer signs long-term agreement to supply Prevenar 13 to world's poorest countries.
Investor Presentations
Access the Pfizer Presentation Archive to view Executive Leadership presentations to shareholders, analysts, and global health care conferences.
Executive Speeches & Commentary
View Executive Leadership speeches on a variety of topics.
Pfizer Pipeline Update – Our Medicines in Development
Visit the Pfizer Pipeline to learn more about exciting breakthroughs with our medicines in development.
Stay on top of Pfizer breaking news: Get News Alerts by RSS.
Follow us
Pfizer Twitter Community
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
Stock Symbol: PFE Stock Exchange: NYSE
Stock Quote at: May 21 2013 4:00PM
| Last 28.78 | Change 0.08 |
| %Change | 0.28 | Vol. | 44,108,300 |
| Day High | 28.83 | 52 Wk. High | 31.15 |
| Day Low | 28.31 | 52 Wk. Low | 21.40 |
| Open | 28.71 | Mkt. Cap(Bil) | 204.14 |
| Prev. Close | 28.70 |
Our press kit provides information that might help you write stories or simply find out more about Pfizer.
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Health Care Professionals
- Privacy Policy
Copyright © 2002–2013 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc. is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.